{"ticker": {"uuid": "8ae7d703-1a45-4a80-8791-d5a3afec4d6d", "symbol": "RLYB", "name": "Rallybio Corp", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Rallybio Corporation (NASDAQ: RLYB) to merge and rebrand as Avenzo Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNek85RHFZdklQc1ZJYkVBMmtxMWxGaVVFOV9kRGdrRWlxUnRKd1BLdkdfdV9ySExVRktadGtoZjhMMnpIU2J3dG8talRoOHktRWQ1NDlZbVJuRThCMW1jN0UyVlBVLTZLRkpFMzZob2tmaUlKeE1OMnNNaG1xejZFZnI0b2d0Y2RjV0VGaWEyd2JXb21EQVhHN2REY1ROSlJUcVlDNmxJMFQtdlRpWFRRXzM5MA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T21:21:45+00:00", "published_display": "15 Jul 2026 21:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Rallybio Corporation \u2013 NASDAQ:RLYB", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQWXpubFFoenpNbm0xZkk0RnI1OW1YU2tkTEV3M3pUNlVmenN2VFlVdF9JTjIwYmMzUDhVQ0ZnS3l6OUcyMXdqZTBURmpYUVp4dDZjVEtmdGRac3NPNnB6VkNjS1lrdWFQdndiRXpUMzkxSldxV0lVcTRDYkhnSWtVcHdUMjZrZVRsSHl0cVY1aHdOVjQ0bHczcTVOQXNtZWYwTkE?oc=5", "source_name": "TradingView", "published_at": "2026-07-15T13:52:38+00:00", "published_display": "15 Jul 2026 13:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Rallybio Corp (RLYB) director exercises stock options, lifts stake to 6,542 shares", "summary": "Rallybio Corp director Helen M. Boudreau exercised options to acquire 3,562 shares of Common Stock on July 6, 2026, at an exercise price of $2.38 per share. This transaction increased her direct holdings to 6,542 shares. The exercised options were \"Right to Buy\" with an expiratio", "url": "https://www.stocktitan.net/sec-filings/RLYB/form-4-rallybio-corp-insider-trading-activity-5e44e6d6b1b7.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:39:52", "published_display": "10 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio Corp (RLYB) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Rallybio Corp (RLYB) has an earnings forecast score of 6.00, placing it 333rd out of 389 in the Biotechnology & Medical Research industry. Analysts have a consensus price target of $1.00 for RLYB, with one analyst currently holding a \"Hold\" rating for the stock. The company's EPS", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rlyb/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T00:39:00", "published_display": "18 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio Corp (RLYB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Rallybio Corp (RLYB), focusing on business segments, regional revenue, and profit contribution. It notes that relevant data for FY2025 and FY2024 has not yet been disclosed by the company, though it does show a United States revenue o", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rlyb/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T22:10:07", "published_display": "17 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio Corp (RLYB) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical data on dividends and stock splits for Rallybio Corp (RLYB). It states that Rallybio Corp has distributed no dividends over the past five years and lists one upcoming stock split event: a merger with an 8-to-1 ratio scheduled for January 29, 2026.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rlyb/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:10:07", "published_display": "17 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United States - Mintz Advising On $215 Million Private Placement Concurrent With Avenzo Therapeutics\u2019 And Rallybio\u2019s Merger Transaction", "summary": "Mintz is advising the placement agents for a $215 million private placement that will close concurrently with the merger transaction between Avenzo Therapeutics, Inc. and Rallybio Corporation. The Mintz team, including capital markets, regulatory, and intellectual property adviso", "url": "https://www.mondaq.com/pressrelease/198194/mintz-advising-on-%24215-million-private-placement-concurrent-with-avenzo-therapeutics-and-rallybios-merger-transaction", "source_name": "Mondaq", "published_at": "2026-06-08T15:39:15", "published_display": "08 Jun 2026 15:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADAR1, Daniel Schneeberger disclose 17.5% stake in Rallybio (RLYB)", "summary": "ADAR1 Capital Management, LLC and Daniel Schneeberger have disclosed a 17.5% stake in Rallybio (RLYB), owning 926,352 shares through private funds and separately managed accounts. This disclosure was made via a Schedule 13G filing, indicating a passive investment intent. Daniel S", "url": "https://www.stocktitan.net/sec-filings/RLYB/schedule-13g-rallybio-corp-passive-investment-disclosure-5-41585ea0b455.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:39:04", "published_display": "05 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adar1 Capital, Daniel Schneeberger buy $2.18m Rallybio stock", "summary": "ADAR1 Capital Management, LLC and Daniel Schneeberger collectively purchased approximately $2.18 million worth of Rallybio Corp (NASDAQ:RLYB) common stock on May 4 and 5, 2026. This insider buying activity occurs as RLYB trades near its 52-week high after a 505% gain over the pas", "url": "https://www.investing.com/news/insider-trading-news/adar1-capital-daniel-schneeberger-buy-218m-rallybio-stock-93CH-4666109", "source_name": "Investing.com", "published_at": "2026-06-05T03:09:32", "published_display": "05 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB", "summary": "Kahn Swick & Foti, LLC (KSF) is investigating the proposed merger of Rallybio Corporation (RLYB) and Avenzo Therapeutics, Inc., following which current Rallybio equityholders are expected to own approximately 2.8% of the combined company. KSF aims to determine if the merger and i", "url": "https://www.businesswire.com/news/home/20260602266487/en/Rallybio-Investor-Alert-Kahn-Swick-Foti-LLC-Investigates-Merger-of-Rallybio-Corporation---RLYB", "source_name": "Business Wire", "published_at": "2026-06-03T07:40:07", "published_display": "03 Jun 2026 07:40", "sentiment": "negative", "sentiment_pct": 36, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholder Alert: Ademi LLP investigates whether Rallybio Corporation is obtaining a Fair Price for Public Shareholders", "summary": "Ademi LLP is investigating Rallybio (Nasdaq: RLY) regarding its recently announced transaction with Avenzo Therapeutics, citing potential breaches of fiduciary duty and other legal violations. Rallybio equityholders are expected to own only 2.8% of the combined company, while Ave", "url": "https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-rallybio-corporation-is-obtaining-a-fair-price-for-public-shareholders-302788854.html", "source_name": "PR Newswire", "published_at": "2026-06-02T16:14:37", "published_display": "02 Jun 2026 16:14", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of", "summary": "Brodsky & Smith LLC is investigating several companies, including Taylor Morrison Home Corporation, Rallybio Corporation, InMed Pharmaceuticals, Inc., and KalVista Pharmaceuticals, Inc., for potential breaches of fiduciary duties. The investigations focus on whether the proposed ", "url": "https://www.globenewswire.com/news-release/2026/06/02/3305455/0/en/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-taylor-morrison-home-corporation-nyse-tmhc-rallybio-corporation-nasdaq-rlyb-inmed-pharmaceutica.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T15:51:00", "published_display": "02 Jun 2026 15:51", "sentiment": "negative", "sentiment_pct": 38, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo \u2013 How Much Of The New Company Will Rallybio Shareholders Own?", "summary": "Rallybio (RLYB) shares surged over 20% to a two-year high after announcing a merger agreement with Avenzo Therapeutics. The combined entity, which will operate as Avenzo Therapeutics and trade under AVZO, will focus on oncology and has secured $215 million in financing. Existing ", "url": "https://stocktwits.com/news-articles/markets/equity/rlyb-stock-rallies-on-avenzo-merger/cZ0gUckReH6", "source_name": "Stocktwits", "published_at": "2026-06-02T11:40:38", "published_display": "02 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement", "summary": "Rallybio Corporation and Avenzo Therapeutics have announced a merger agreement to advance next-generation oncology therapies, with the combined company to operate as Avenzo Therapeutics. Avenzo also secured a $215 million oversubscribed private placement financing, expected to fu", "url": "https://ca.finance.yahoo.com/news/rallybio-corporation-avenzo-therapeutics-announce-120000779.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-06-02T07:10:25", "published_display": "02 Jun 2026 07:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio to Merge With Avenzo in Stock Deal; $215 Million Financing Planned", "summary": "Rallybio (RLYB) announced a stock-for-stock merger agreement with Avenzo Therapeutics, which will result in a rebrand to Avenzo Therapeutics and a $215 million private placement. This financing is a closing condition and will fund the combined company, with pro forma ownership si", "url": "https://www.tradingview.com/news/tradingview:86999f6e9e8be:0-rallybio-to-merge-with-avenzo-in-stock-deal-215-million-financing-planned/", "source_name": "TradingView", "published_at": "2026-06-02T05:40:05", "published_display": "02 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer drug startup Avenzo gets $215M as it goes public via Rallybio merger", "summary": "Rallybio Corporation and Avenzo Therapeutics have announced a merger agreement, under which Avenzo will go public and receive $215 million in a private placement. The combined company will operate as Avenzo Therapeutics, focusing on next-generation oncology therapies, including s", "url": "https://www.stocktitan.net/news/RLYB/rallybio-corporation-and-avenzo-therapeutics-announce-merger-pm7oo10xsdeg.html", "source_name": "Stock Titan", "published_at": "2026-06-01T17:11:04", "published_display": "01 Jun 2026 17:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio Agrees to Acquire Avenzo Therapeutics", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rallybio-agrees-acquire-avenzo-therapeutics-124920814.html", "source_name": "MT Newswires", "published_at": "2026-06-01T12:49:20+00:00", "published_display": "01 Jun 2026 12:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio amends employment and separation agreements for Stephen Uden, Jonathan Lieber and Steven Ryder", "summary": "Rallybio (RLYB) has amended the employment agreements for Stephen Uden and Jonathan Lieber, and a separation agreement for Steven Ryder. These amendments specify that the upcoming Merger will be considered a change in control. This change ensures that the individuals are eligible", "url": "https://www.tradingview.com/news/tradingview:743f5bdcbae5c:0-rallybio-amends-employment-and-separation-agreements-for-stephen-uden-jonathan-lieber-and-steven-ryder/", "source_name": "TradingView", "published_at": "2026-06-01T12:39:23", "published_display": "01 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio (NASDAQ: RLYB) to merge into Avenzo Therapeutics with $215M private financing and CVRs", "summary": "Rallybio (NASDAQ: RLYB) announced a definitive merger agreement with Avenzo Therapeutics, a clinical-stage biotechnology company. The transaction involves Rallybio acquiring Avenzo in an all-stock reverse-triangular merger, coupled with a concurrent oversubscribed private placeme", "url": "https://www.stocktitan.net/sec-filings/RLYB/8-k-rallybio-corp-reports-material-event-8a7f2dcbdd76.html", "source_name": "Stock Titan", "published_at": "2026-06-01T11:39:23", "published_display": "01 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RallyBio tries again for reverse merger, this time with Avenzo", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPX0JGWm9pVHVoWElpcU1rcmZZTDVUMGJzclI5eVNmTzktSzhFT09WTFhFR19OaVQxU196NF96ckNqMnluaE9zMGJNTTZieW9RT0VTVmlPVVljVW1Wa0Z5UEpNYnFCWTFlZFBiRjRtSkZRS3BZc082aHBvZWNneGZQNFBzVDRXZlVYQVdpRkhVSQ?oc=5", "source_name": "BioPharma Dive", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPdUNKRVpMMldfSXBFVjNDaHZ1QzU1c3ZmSjVYQl9zV1Y4aTZGeExTbWROU0dTNjZuS2ZiWU1DQUs5X3lBcEhiU0Fvc2liMkREdmtOY2VsaFpZb09pV3h2d2NxelBEQUZ4eTM3T2d5MnhfMmtNdGFVVVBXZ2J5b3hiMUJVUmYwUHVOUmJMcTBzalhwdDdtbFRPcGIwbXhMVUVtakpSSG5sWHdHWDEzaEd5YVhFZmc5Q3BpU0w5QkwySHNPcUd4NWZTalFB?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio to merge with Avenzo Therapeutics in $215M deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNREdKcXpMWHNEQlBhSDN6U3Q4RnVrUXBaMjMxX1M0QklMeHc5TkJWak93SmZZdFR6Wmxaa0hONUR4UldVOXNDRHZWZHNtNE9UWWxDZEhPZHZ5emxFR0EyeUJ5U0dHVlFBWlRVcjk2YkVPdzJfU1l5STB0WEZ4MTZTRFB2dkRqQW1YWDJR?oc=5", "source_name": "grafa.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its Shareholders", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQaWRNTUxYSDZJRlpIcE1UejRtNGtnc3pTUUtNZjlWNWxHQkpLeDJvX0VKaVY0NkN1TkVjQ245UHRZem5DSGZRMFdFSC1WMDd6M3AzYmN6YS1RMUkwT3dOU1d2WXFzbklHc0U2STdiS2pnZU9iMzdDeG1lOFVhSy1OYlY5dGg0dm5hWUVsM0kwZEpqRXp2M2E1OW1VUEloQkpNZDVzNUlJeURYN2llbHJoZzdRZEgtc1hJM0RnUmlOd1plcWhKdnFkZ2NpVjZSaDBnV3QwNThRT1FLTkFxVlpBSm1wY2s2STA?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RLYB - Rallybio Corp Stock Price and Quote", "summary": "Rallybio Corp (RLYB) closed at $15.94, showing a slight increase of 0.19%. The company, which specializes in biotechnology products for rare diseases, has a market cap of $84.45M and a significant insider ownership of 34.53%. Recent news includes merger agreements with Avenzo The", "url": "https://finviz.com/stock?t=RLYB", "source_name": "Finviz", "published_at": "2026-05-28T08:39:25", "published_display": "28 May 2026 08:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio Analyst Ratings and Price Targets | NASDAQ:RLYB", "summary": "Rallybio Corp (NASDAQ:RLYB) has a consensus price target of $8.88 from 7 analysts, with a high of $15 and a low of $1.50. Recent analyst ratings indicate a potential downside, with HC Wainwright & Co. setting an average price target of $5. The article also details recent downgrad", "url": "https://www.benzinga.com/quote/RLYB/analyst-ratings", "source_name": "Benzinga", "published_at": "2026-05-28T03:39:51", "published_display": "28 May 2026 03:39", "sentiment": "negative", "sentiment_pct": 14, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio (Nasdaq:RLYB) - Stock Analysis", "summary": "Rallybio Corporation (RLYB) is a clinical-stage biotechnology company developing therapies for rare diseases. The company faces significant financial risks, including low revenue, unprofitability, and high stock price volatility, alongside concerns about its cash runway. Recently", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rlyb/rallybio", "source_name": "Simply Wall Street", "published_at": "2026-05-24T13:10:26", "published_display": "24 May 2026 13:10", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adar1 Capital Management, Daniel Schneeberger buy $226k Rallybio stock", "summary": "ADAR1 Capital Management and its manager, Daniel Schneeberger, collectively purchased approximately $226,563 worth of Rallybio Corp (NASDAQ:RLYB) common stock across two days in May 2026. These insider transactions involved 16,209 shares, acquired at prices ranging from $13.80 to", "url": "https://in.investing.com/news/insider-trading-news/adar1-capital-management-daniel-schneeberger-buy-226k-rallybio-stock-93CH-5419486", "source_name": "Investing.com India", "published_at": "2026-05-21T12:39:10", "published_display": "21 May 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADAR1-managed funds boost Rallybio (RLYB) stake with open-market share buys", "summary": "ADAR1 Capital Management, LLC, through its managed funds and accounts, increased its stake in Rallybio Corp (RLYB) by purchasing 16,209 shares in open-market transactions on May 18-19, 2026. These shares were bought at weighted average prices near $14 per share, bringing the tota", "url": "https://www.stocktitan.net/sec-filings/RLYB/form-4-rallybio-corp-insider-trading-activity-f31cc654e07b.html", "source_name": "Stock Titan", "published_at": "2026-05-21T01:11:11", "published_display": "21 May 2026 01:11", "sentiment": "positive", "sentiment_pct": 87, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio Stock (RLYB) Opinions on Merger Termination Fee and Insider Buys | RLYB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNVTdoekloU291TzhXbUNGbm9tQm9zdFdIVXVtV3pjYlBWOUozOUdUS1RZTWUzbFVndllPSGM3UFUxaUlUd1lMeS15alUxcFVibVdHeW9tOHlYcmt0enJXNVNBMkJBOHJ0bFF2dnJmN1gxWWk5UGhMTXlxeGt5UUhBNFFrdkN5SUxPNnlDY3BTRmIySTM1T2dwNGpCU0UyTVczMWZIdm1WNjM5S1VMR0Q0?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adar1 Capital Management buys $1.11m of Rallybio (RLYB) stock", "summary": "Adar1 Capital Management, LLC and Daniel Schneeberger, who together own over 10% of Rallybio Corp (NASDAQ:RLYB), purchased more than $1.11 million worth of the company's common stock. These insider purchases, occurring on May 13 and May 15, 2026, were made at prices ranging from ", "url": "https://www.investing.com/news/insider-trading-news/adar1-capital-management-buys-111m-of-rallybio-rlyb-stock-93CH-4694338", "source_name": "Investing.com", "published_at": "2026-05-16T22:13:07", "published_display": "16 May 2026 22:13", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Stock Purchases: May 16, 2026", "summary": "The article summarizes significant insider stock purchases reported on May 16, 2026, highlighting transactions for companies like RALLYBIO CORP ($RLYB), ALPHA METALLURGICAL RESOURCES, INC. ($AMR), KBR, INC. ($KBR), DUTCH BROS INC. ($BROS), and GPGI, INC. It details the number of ", "url": "https://www.quiverquant.com/news/Insider+Stock+Purchases:+May+16,+2026", "source_name": "Quiver Quantitative", "published_at": "2026-05-16T21:40:29", "published_display": "16 May 2026 21:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADAR1 funds boost Rallybio (RLYB) stake with May open-market buys", "summary": "ADAR1 Capital Management, LLC and Daniel Schneeberger reported significant open-market purchases of Rallybio Corp (RLYB) common stock in May 2026. The entities acquired a total of 79,559 shares across several transactions, with prices ranging from $13.77 to $14.00 per share. Thes", "url": "https://www.stocktitan.net/sec-filings/RLYB/form-4-rallybio-corp-insider-trading-activity-371eee2e993f.html", "source_name": "Stock Titan", "published_at": "2026-05-16T01:10:59", "published_display": "16 May 2026 01:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Global Group (RLYB) discloses 528,954 shares, 9.99% stake", "summary": "Viking Global-related reporting persons have disclosed a 9.99% stake in Rallybio Corporation (RLYB), totaling 528,954 shares. This includes 524,347 directly owned shares and 4,607 shares from Warrants, with the total beneficial ownership capped at 9.99% due to a contractual \"Bloc", "url": "https://www.stocktitan.net/sec-filings/RLYB/schedule-13g-a-rallybio-corp-amended-passive-investment-disclosure-8e10b6060a5d.html", "source_name": "Stock Titan", "published_at": "2026-05-15T22:11:00", "published_display": "15 May 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Adar1 capital, manager Daniel Schneeberger buy $711,054 Rallybio stock.", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPVmZ3c2R1VlJuYVhhUnhEYkFxbnRvZXVxVWNfMFVOcDVNVkNVbXpvT3NSY0pabmtlT3pCNjJwbnJ6VXVaNFJ5aWN2dTI4Z1YzUzE1QkZFeUEtZExxMFdIWmVhaU5CMEFNUFlhbVgwRjVpWlpBSXB4ampXZUxlOUw2VWVqNzY5WmZFR0FhQVR5czJGb3BUTGt6cXFFRjNRMUNWX3Y1anhVU1dYNnhVUXJrejllV0lDTVhtVUV3QlpjY3MwdlhBWmJLNTc0VU0?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Driving Rallybio's Recent Surge and Investor Interest", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPYl96cldfbHNfd1huM18zamZfUDhpNTNkYktRUGViRlFKUWRBb0lZSjdXcHhLWVo4RmJKWHZzZEd3Tjd1U3BxU2dEa05fUm1VUlp2c0VncFhkOWJub0xqZVVwMTc5SjRxRkdvMzJQbExDQXJlLWVZRHVWLUQ1Slh3cmE5QWg3bWNvMFFrWmdSaUpnNWk5NmRWcllYaw?oc=5", "source_name": "Kavout | AI", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "[RW] Rallybio Corp SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOaU9vSC05ZTRwQTNCN0gxVjQ3WHlINzZSa1E3dk9nMU5MTU0wVmtvUTVwN2VMenpIb1dBd0JDT214Q3ptS2IyUi1nSDRZYTJHU3dkcTNEVWU4WDFyeG9aczdmdjBXemUzbkFNdUZ3d0dRM29BelBId1ZYMnFRREVxb01JRk1fdVpJeVV0dUo4LXhUanc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio stock surges after receiving $50M termination fee", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxORkt2YWI4VnA5Q0V1TDFTVHRVMGZRQ2VMLUJqbWVJX1IxM29SSzJTa0RjUUtERzZjeWYzQ2ZuN29EQm1Yc01EaFRIdTZNSXJsZ2hFQVI5Sm11X0FCUzZSREg5TzdaTE1aLUptckZmUXVZLVdITE1Ia1lTb2NOYjJXODFucmNwSnUwQ1V5a1RBWFBRQUZqQ1dXMUlCZEc2RzNHblpDTF9hUVhsS2M2RVdZcXVjV25Id1lzcGc0?oc=5", "source_name": "Investing.com", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Rallybio to acquire Candid Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOSVVpaGZyd2p6THg1ZWlLWndJcVdjRlJGT0F5VGhZc1ZXOVJnYmxUeTgtUUZxd2laR3AxWnkwVWljdXVDVGd0a1E4bmRKLVdkY3pfOTJvLVBjRnJIUDlYcmVsTmhsUDgxRW9BWEwzbC1jbnRLYWdqeU8teEVwU3ZFSXhIT05iLWgzeHc?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio to merge with San Diego biotech in deal backed by $505M in financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNNmhONGJnaDNUR0JKNzBfUVN4eDJXOHVzbUJ4UWNJVXFfWXZwX1F5UGtZTHB3ZWMyLUNNTWJRRGJiUnpTSWVIbFRVSWViNVdYdm9ObHBJVkxYOEVtUDF2bEFBSFg1X0VFYlJSYmZQTEdJeHhMZUplY2FRbHFKc0FwLXZ6MXJSWFVuQl9FU2lSVTQxbnRYYkdxbmZldXI4V3hpcHFLalotdkxQY3ZWSGF6aTJMUUQ?oc=5", "source_name": "Hartford Business Journal", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio Corp USD0.0001 share price | RLYB", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPOVIzc0FXeHhvZmxIYlB5cWRiZlRCU2tXZG9rMEJsQ2RaM0JnbUNhZTFkM0dFRlY2WE54ZDl1aERUSGYzMnNQazljQm4tVThPRFBTSnZVVjVTTUpkMlppcU9BSlhqV054cTNIcDQ1dm5QRVVjbjFXR3lJd0w3NEJNUA?oc=5", "source_name": "Hargreaves Lansdown", "published_at": "2026-02-10T05:21:49+00:00", "published_display": "10 Feb 2026 05:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio Announces Reverse Stock Split of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNaE9wWVREd2VyTGJvdnQ5b3B2TE5lMlJiZG5Mb0ZhZl83MGRRRGhwYml1WDM0UjFnaXVsMnh6OUY4SnE0OGU2V3lOQjdDRWgxX3pMWGI4Uy15VWU1X0x2dFlaSGhoTC02clRQNFZYdXR5dTVGUFRELWlvV09rdXRoZWNMeWpOSTRaSnoxVGxsejhQMTFjc3pRc3JVUUpFQmU4bzN6SXNMVy13aDBDUlZIMA?oc=5", "source_name": "Business Wire", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 Advances", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNSDJKMlpBLVBSdGVza1otWm1PZU52R09BTWgtR3QwWWFZV0I1emQxdWYxMXN2SnhaMEp3UC04eTZ6c1N0TXBXajJSbGprMHB0YTE2cGlxMDhVWnZGQjUyS1JVSV9vdVZjRjJqV1pWSXl6U0VVREE5VjNMZFJIVDJPLTk2U1JMTnFnT2s1dzdzai0xUQ?oc=5", "source_name": "Market source", "published_at": "2025-09-21T07:00:00+00:00", "published_display": "21 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio (RLYB) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBrN1BGMTVSMmRvWmhxTHVlamo5b09feTFuMkZhRklFRk1jcVF3QmJfOXZXeHJoYm00SDk5VlVFbGJVb3lIc0hhOU5LZWdVNTRqX3pKVmtSWU9zZw?oc=5", "source_name": "MarketBeat", "published_at": "2021-07-30T23:24:33+00:00", "published_display": "30 Jul 2021 23:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Rallybio Corporation (NASDAQ: RLYB) to merge and rebrand as Avenzo Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNek85RHFZdklQc1ZJYkVBMmtxMWxGaVVFOV9kRGdrRWlxUnRKd1BLdkdfdV9ySExVRktadGtoZjhMMnpIU2J3dG8talRoOHktRWQ1NDlZbVJuRThCMW1jN0UyVlBVLTZLRkpFMzZob2tmaUlKeE1OMnNNaG1xejZFZnI0b2d0Y2RjV0VGaWEyd2JXb21EQVhHN2REY1ROSlJUcVlDNmxJMFQtdlRpWFRRXzM5MA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T21:21:45+00:00", "published_display": "15 Jul 2026 21:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Rallybio Corporation \u2013 NASDAQ:RLYB", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQWXpubFFoenpNbm0xZkk0RnI1OW1YU2tkTEV3M3pUNlVmenN2VFlVdF9JTjIwYmMzUDhVQ0ZnS3l6OUcyMXdqZTBURmpYUVp4dDZjVEtmdGRac3NPNnB6VkNjS1lrdWFQdndiRXpUMzkxSldxV0lVcTRDYkhnSWtVcHdUMjZrZVRsSHl0cVY1aHdOVjQ0bHczcTVOQXNtZWYwTkE?oc=5", "source_name": "TradingView", "published_at": "2026-07-15T13:52:38+00:00", "published_display": "15 Jul 2026 13:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio Corp (RLYB) director exercises stock options, lifts stake to 6,542 shares", "summary": "Rallybio Corp director Helen M. Boudreau exercised options to acquire 3,562 shares of Common Stock on July 6, 2026, at an exercise price of $2.38 per share. This transaction increased her direct holdings to 6,542 shares. The exercised options were \"Right to Buy\" with an expiratio", "url": "https://www.stocktitan.net/sec-filings/RLYB/form-4-rallybio-corp-insider-trading-activity-5e44e6d6b1b7.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:39:52", "published_display": "10 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio Corp (RLYB) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Rallybio Corp (RLYB) has an earnings forecast score of 6.00, placing it 333rd out of 389 in the Biotechnology & Medical Research industry. Analysts have a consensus price target of $1.00 for RLYB, with one analyst currently holding a \"Hold\" rating for the stock. The company's EPS", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rlyb/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T00:39:00", "published_display": "18 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio Corp (RLYB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Rallybio Corp (RLYB), focusing on business segments, regional revenue, and profit contribution. It notes that relevant data for FY2025 and FY2024 has not yet been disclosed by the company, though it does show a United States revenue o", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rlyb/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T22:10:07", "published_display": "17 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio Corp (RLYB) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical data on dividends and stock splits for Rallybio Corp (RLYB). It states that Rallybio Corp has distributed no dividends over the past five years and lists one upcoming stock split event: a merger with an 8-to-1 ratio scheduled for January 29, 2026.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rlyb/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:10:07", "published_display": "17 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "United States - Mintz Advising On $215 Million Private Placement Concurrent With Avenzo Therapeutics\u2019 And Rallybio\u2019s Merger Transaction", "summary": "Mintz is advising the placement agents for a $215 million private placement that will close concurrently with the merger transaction between Avenzo Therapeutics, Inc. and Rallybio Corporation. The Mintz team, including capital markets, regulatory, and intellectual property adviso", "url": "https://www.mondaq.com/pressrelease/198194/mintz-advising-on-%24215-million-private-placement-concurrent-with-avenzo-therapeutics-and-rallybios-merger-transaction", "source_name": "Mondaq", "published_at": "2026-06-08T15:39:15", "published_display": "08 Jun 2026 15:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADAR1, Daniel Schneeberger disclose 17.5% stake in Rallybio (RLYB)", "summary": "ADAR1 Capital Management, LLC and Daniel Schneeberger have disclosed a 17.5% stake in Rallybio (RLYB), owning 926,352 shares through private funds and separately managed accounts. This disclosure was made via a Schedule 13G filing, indicating a passive investment intent. Daniel S", "url": "https://www.stocktitan.net/sec-filings/RLYB/schedule-13g-rallybio-corp-passive-investment-disclosure-5-41585ea0b455.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:39:04", "published_display": "05 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adar1 Capital, Daniel Schneeberger buy $2.18m Rallybio stock", "summary": "ADAR1 Capital Management, LLC and Daniel Schneeberger collectively purchased approximately $2.18 million worth of Rallybio Corp (NASDAQ:RLYB) common stock on May 4 and 5, 2026. This insider buying activity occurs as RLYB trades near its 52-week high after a 505% gain over the pas", "url": "https://www.investing.com/news/insider-trading-news/adar1-capital-daniel-schneeberger-buy-218m-rallybio-stock-93CH-4666109", "source_name": "Investing.com", "published_at": "2026-06-05T03:09:32", "published_display": "05 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB", "summary": "Kahn Swick & Foti, LLC (KSF) is investigating the proposed merger of Rallybio Corporation (RLYB) and Avenzo Therapeutics, Inc., following which current Rallybio equityholders are expected to own approximately 2.8% of the combined company. KSF aims to determine if the merger and i", "url": "https://www.businesswire.com/news/home/20260602266487/en/Rallybio-Investor-Alert-Kahn-Swick-Foti-LLC-Investigates-Merger-of-Rallybio-Corporation---RLYB", "source_name": "Business Wire", "published_at": "2026-06-03T07:40:07", "published_display": "03 Jun 2026 07:40", "sentiment": "negative", "sentiment_pct": 36, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholder Alert: Ademi LLP investigates whether Rallybio Corporation is obtaining a Fair Price for Public Shareholders", "summary": "Ademi LLP is investigating Rallybio (Nasdaq: RLY) regarding its recently announced transaction with Avenzo Therapeutics, citing potential breaches of fiduciary duty and other legal violations. Rallybio equityholders are expected to own only 2.8% of the combined company, while Ave", "url": "https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-rallybio-corporation-is-obtaining-a-fair-price-for-public-shareholders-302788854.html", "source_name": "PR Newswire", "published_at": "2026-06-02T16:14:37", "published_display": "02 Jun 2026 16:14", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of", "summary": "Brodsky & Smith LLC is investigating several companies, including Taylor Morrison Home Corporation, Rallybio Corporation, InMed Pharmaceuticals, Inc., and KalVista Pharmaceuticals, Inc., for potential breaches of fiduciary duties. The investigations focus on whether the proposed ", "url": "https://www.globenewswire.com/news-release/2026/06/02/3305455/0/en/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-taylor-morrison-home-corporation-nyse-tmhc-rallybio-corporation-nasdaq-rlyb-inmed-pharmaceutica.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T15:51:00", "published_display": "02 Jun 2026 15:51", "sentiment": "negative", "sentiment_pct": 38, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo \u2013 How Much Of The New Company Will Rallybio Shareholders Own?", "summary": "Rallybio (RLYB) shares surged over 20% to a two-year high after announcing a merger agreement with Avenzo Therapeutics. The combined entity, which will operate as Avenzo Therapeutics and trade under AVZO, will focus on oncology and has secured $215 million in financing. Existing ", "url": "https://stocktwits.com/news-articles/markets/equity/rlyb-stock-rallies-on-avenzo-merger/cZ0gUckReH6", "source_name": "Stocktwits", "published_at": "2026-06-02T11:40:38", "published_display": "02 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement", "summary": "Rallybio Corporation and Avenzo Therapeutics have announced a merger agreement to advance next-generation oncology therapies, with the combined company to operate as Avenzo Therapeutics. Avenzo also secured a $215 million oversubscribed private placement financing, expected to fu", "url": "https://ca.finance.yahoo.com/news/rallybio-corporation-avenzo-therapeutics-announce-120000779.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-06-02T07:10:25", "published_display": "02 Jun 2026 07:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio to Merge With Avenzo in Stock Deal; $215 Million Financing Planned", "summary": "Rallybio (RLYB) announced a stock-for-stock merger agreement with Avenzo Therapeutics, which will result in a rebrand to Avenzo Therapeutics and a $215 million private placement. This financing is a closing condition and will fund the combined company, with pro forma ownership si", "url": "https://www.tradingview.com/news/tradingview:86999f6e9e8be:0-rallybio-to-merge-with-avenzo-in-stock-deal-215-million-financing-planned/", "source_name": "TradingView", "published_at": "2026-06-02T05:40:05", "published_display": "02 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer drug startup Avenzo gets $215M as it goes public via Rallybio merger", "summary": "Rallybio Corporation and Avenzo Therapeutics have announced a merger agreement, under which Avenzo will go public and receive $215 million in a private placement. The combined company will operate as Avenzo Therapeutics, focusing on next-generation oncology therapies, including s", "url": "https://www.stocktitan.net/news/RLYB/rallybio-corporation-and-avenzo-therapeutics-announce-merger-pm7oo10xsdeg.html", "source_name": "Stock Titan", "published_at": "2026-06-01T17:11:04", "published_display": "01 Jun 2026 17:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio Agrees to Acquire Avenzo Therapeutics", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rallybio-agrees-acquire-avenzo-therapeutics-124920814.html", "source_name": "MT Newswires", "published_at": "2026-06-01T12:49:20+00:00", "published_display": "01 Jun 2026 12:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio amends employment and separation agreements for Stephen Uden, Jonathan Lieber and Steven Ryder", "summary": "Rallybio (RLYB) has amended the employment agreements for Stephen Uden and Jonathan Lieber, and a separation agreement for Steven Ryder. These amendments specify that the upcoming Merger will be considered a change in control. This change ensures that the individuals are eligible", "url": "https://www.tradingview.com/news/tradingview:743f5bdcbae5c:0-rallybio-amends-employment-and-separation-agreements-for-stephen-uden-jonathan-lieber-and-steven-ryder/", "source_name": "TradingView", "published_at": "2026-06-01T12:39:23", "published_display": "01 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio (NASDAQ: RLYB) to merge into Avenzo Therapeutics with $215M private financing and CVRs", "summary": "Rallybio (NASDAQ: RLYB) announced a definitive merger agreement with Avenzo Therapeutics, a clinical-stage biotechnology company. The transaction involves Rallybio acquiring Avenzo in an all-stock reverse-triangular merger, coupled with a concurrent oversubscribed private placeme", "url": "https://www.stocktitan.net/sec-filings/RLYB/8-k-rallybio-corp-reports-material-event-8a7f2dcbdd76.html", "source_name": "Stock Titan", "published_at": "2026-06-01T11:39:23", "published_display": "01 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RallyBio tries again for reverse merger, this time with Avenzo", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPX0JGWm9pVHVoWElpcU1rcmZZTDVUMGJzclI5eVNmTzktSzhFT09WTFhFR19OaVQxU196NF96ckNqMnluaE9zMGJNTTZieW9RT0VTVmlPVVljVW1Wa0Z5UEpNYnFCWTFlZFBiRjRtSkZRS3BZc082aHBvZWNneGZQNFBzVDRXZlVYQVdpRkhVSQ?oc=5", "source_name": "BioPharma Dive", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPdUNKRVpMMldfSXBFVjNDaHZ1QzU1c3ZmSjVYQl9zV1Y4aTZGeExTbWROU0dTNjZuS2ZiWU1DQUs5X3lBcEhiU0Fvc2liMkREdmtOY2VsaFpZb09pV3h2d2NxelBEQUZ4eTM3T2d5MnhfMmtNdGFVVVBXZ2J5b3hiMUJVUmYwUHVOUmJMcTBzalhwdDdtbFRPcGIwbXhMVUVtakpSSG5sWHdHWDEzaEd5YVhFZmc5Q3BpU0w5QkwySHNPcUd4NWZTalFB?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio to merge with Avenzo Therapeutics in $215M deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxNREdKcXpMWHNEQlBhSDN6U3Q4RnVrUXBaMjMxX1M0QklMeHc5TkJWak93SmZZdFR6Wmxaa0hONUR4UldVOXNDRHZWZHNtNE9UWWxDZEhPZHZ5emxFR0EyeUJ5U0dHVlFBWlRVcjk2YkVPdzJfU1l5STB0WEZ4MTZTRFB2dkRqQW1YWDJR?oc=5", "source_name": "grafa.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its Shareholders", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQaWRNTUxYSDZJRlpIcE1UejRtNGtnc3pTUUtNZjlWNWxHQkpLeDJvX0VKaVY0NkN1TkVjQ245UHRZem5DSGZRMFdFSC1WMDd6M3AzYmN6YS1RMUkwT3dOU1d2WXFzbklHc0U2STdiS2pnZU9iMzdDeG1lOFVhSy1OYlY5dGg0dm5hWUVsM0kwZEpqRXp2M2E1OW1VUEloQkpNZDVzNUlJeURYN2llbHJoZzdRZEgtc1hJM0RnUmlOd1plcWhKdnFkZ2NpVjZSaDBnV3QwNThRT1FLTkFxVlpBSm1wY2s2STA?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RLYB - Rallybio Corp Stock Price and Quote", "summary": "Rallybio Corp (RLYB) closed at $15.94, showing a slight increase of 0.19%. The company, which specializes in biotechnology products for rare diseases, has a market cap of $84.45M and a significant insider ownership of 34.53%. Recent news includes merger agreements with Avenzo The", "url": "https://finviz.com/stock?t=RLYB", "source_name": "Finviz", "published_at": "2026-05-28T08:39:25", "published_display": "28 May 2026 08:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio Analyst Ratings and Price Targets | NASDAQ:RLYB", "summary": "Rallybio Corp (NASDAQ:RLYB) has a consensus price target of $8.88 from 7 analysts, with a high of $15 and a low of $1.50. Recent analyst ratings indicate a potential downside, with HC Wainwright & Co. setting an average price target of $5. The article also details recent downgrad", "url": "https://www.benzinga.com/quote/RLYB/analyst-ratings", "source_name": "Benzinga", "published_at": "2026-05-28T03:39:51", "published_display": "28 May 2026 03:39", "sentiment": "negative", "sentiment_pct": 14, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio (Nasdaq:RLYB) - Stock Analysis", "summary": "Rallybio Corporation (RLYB) is a clinical-stage biotechnology company developing therapies for rare diseases. The company faces significant financial risks, including low revenue, unprofitability, and high stock price volatility, alongside concerns about its cash runway. Recently", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rlyb/rallybio", "source_name": "Simply Wall Street", "published_at": "2026-05-24T13:10:26", "published_display": "24 May 2026 13:10", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adar1 Capital Management, Daniel Schneeberger buy $226k Rallybio stock", "summary": "ADAR1 Capital Management and its manager, Daniel Schneeberger, collectively purchased approximately $226,563 worth of Rallybio Corp (NASDAQ:RLYB) common stock across two days in May 2026. These insider transactions involved 16,209 shares, acquired at prices ranging from $13.80 to", "url": "https://in.investing.com/news/insider-trading-news/adar1-capital-management-daniel-schneeberger-buy-226k-rallybio-stock-93CH-5419486", "source_name": "Investing.com India", "published_at": "2026-05-21T12:39:10", "published_display": "21 May 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADAR1-managed funds boost Rallybio (RLYB) stake with open-market share buys", "summary": "ADAR1 Capital Management, LLC, through its managed funds and accounts, increased its stake in Rallybio Corp (RLYB) by purchasing 16,209 shares in open-market transactions on May 18-19, 2026. These shares were bought at weighted average prices near $14 per share, bringing the tota", "url": "https://www.stocktitan.net/sec-filings/RLYB/form-4-rallybio-corp-insider-trading-activity-f31cc654e07b.html", "source_name": "Stock Titan", "published_at": "2026-05-21T01:11:11", "published_display": "21 May 2026 01:11", "sentiment": "positive", "sentiment_pct": 87, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio Stock (RLYB) Opinions on Merger Termination Fee and Insider Buys | RLYB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNVTdoekloU291TzhXbUNGbm9tQm9zdFdIVXVtV3pjYlBWOUozOUdUS1RZTWUzbFVndllPSGM3UFUxaUlUd1lMeS15alUxcFVibVdHeW9tOHlYcmt0enJXNVNBMkJBOHJ0bFF2dnJmN1gxWWk5UGhMTXlxeGt5UUhBNFFrdkN5SUxPNnlDY3BTRmIySTM1T2dwNGpCU0UyTVczMWZIdm1WNjM5S1VMR0Q0?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adar1 Capital Management buys $1.11m of Rallybio (RLYB) stock", "summary": "Adar1 Capital Management, LLC and Daniel Schneeberger, who together own over 10% of Rallybio Corp (NASDAQ:RLYB), purchased more than $1.11 million worth of the company's common stock. These insider purchases, occurring on May 13 and May 15, 2026, were made at prices ranging from ", "url": "https://www.investing.com/news/insider-trading-news/adar1-capital-management-buys-111m-of-rallybio-rlyb-stock-93CH-4694338", "source_name": "Investing.com", "published_at": "2026-05-16T22:13:07", "published_display": "16 May 2026 22:13", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Stock Purchases: May 16, 2026", "summary": "The article summarizes significant insider stock purchases reported on May 16, 2026, highlighting transactions for companies like RALLYBIO CORP ($RLYB), ALPHA METALLURGICAL RESOURCES, INC. ($AMR), KBR, INC. ($KBR), DUTCH BROS INC. ($BROS), and GPGI, INC. It details the number of ", "url": "https://www.quiverquant.com/news/Insider+Stock+Purchases:+May+16,+2026", "source_name": "Quiver Quantitative", "published_at": "2026-05-16T21:40:29", "published_display": "16 May 2026 21:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADAR1 funds boost Rallybio (RLYB) stake with May open-market buys", "summary": "ADAR1 Capital Management, LLC and Daniel Schneeberger reported significant open-market purchases of Rallybio Corp (RLYB) common stock in May 2026. The entities acquired a total of 79,559 shares across several transactions, with prices ranging from $13.77 to $14.00 per share. Thes", "url": "https://www.stocktitan.net/sec-filings/RLYB/form-4-rallybio-corp-insider-trading-activity-371eee2e993f.html", "source_name": "Stock Titan", "published_at": "2026-05-16T01:10:59", "published_display": "16 May 2026 01:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viking Global Group (RLYB) discloses 528,954 shares, 9.99% stake", "summary": "Viking Global-related reporting persons have disclosed a 9.99% stake in Rallybio Corporation (RLYB), totaling 528,954 shares. This includes 524,347 directly owned shares and 4,607 shares from Warrants, with the total beneficial ownership capped at 9.99% due to a contractual \"Bloc", "url": "https://www.stocktitan.net/sec-filings/RLYB/schedule-13g-a-rallybio-corp-amended-passive-investment-disclosure-8e10b6060a5d.html", "source_name": "Stock Titan", "published_at": "2026-05-15T22:11:00", "published_display": "15 May 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Adar1 capital, manager Daniel Schneeberger buy $711,054 Rallybio stock.", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPVmZ3c2R1VlJuYVhhUnhEYkFxbnRvZXVxVWNfMFVOcDVNVkNVbXpvT3NSY0pabmtlT3pCNjJwbnJ6VXVaNFJ5aWN2dTI4Z1YzUzE1QkZFeUEtZExxMFdIWmVhaU5CMEFNUFlhbVgwRjVpWlpBSXB4ampXZUxlOUw2VWVqNzY5WmZFR0FhQVR5czJGb3BUTGt6cXFFRjNRMUNWX3Y1anhVU1dYNnhVUXJrejllV0lDTVhtVUV3QlpjY3MwdlhBWmJLNTc0VU0?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Driving Rallybio's Recent Surge and Investor Interest", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPYl96cldfbHNfd1huM18zamZfUDhpNTNkYktRUGViRlFKUWRBb0lZSjdXcHhLWVo4RmJKWHZzZEd3Tjd1U3BxU2dEa05fUm1VUlp2c0VncFhkOWJub0xqZVVwMTc5SjRxRkdvMzJQbExDQXJlLWVZRHVWLUQ1Slh3cmE5QWg3bWNvMFFrWmdSaUpnNWk5NmRWcllYaw?oc=5", "source_name": "Kavout | AI", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[RW] Rallybio Corp SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOaU9vSC05ZTRwQTNCN0gxVjQ3WHlINzZSa1E3dk9nMU5MTU0wVmtvUTVwN2VMenpIb1dBd0JDT214Q3ptS2IyUi1nSDRZYTJHU3dkcTNEVWU4WDFyeG9aczdmdjBXemUzbkFNdUZ3d0dRM29BelBId1ZYMnFRREVxb01JRk1fdVpJeVV0dUo4LXhUanc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio stock surges after receiving $50M termination fee", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxORkt2YWI4VnA5Q0V1TDFTVHRVMGZRQ2VMLUJqbWVJX1IxM29SSzJTa0RjUUtERzZjeWYzQ2ZuN29EQm1Yc01EaFRIdTZNSXJsZ2hFQVI5Sm11X0FCUzZSREg5TzdaTE1aLUptckZmUXVZLVdITE1Ia1lTb2NOYjJXODFucmNwSnUwQ1V5a1RBWFBRQUZqQ1dXMUlCZEc2RzNHblpDTF9hUVhsS2M2RVdZcXVjV25Id1lzcGc0?oc=5", "source_name": "Investing.com", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio to acquire Candid Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOSVVpaGZyd2p6THg1ZWlLWndJcVdjRlJGT0F5VGhZc1ZXOVJnYmxUeTgtUUZxd2laR3AxWnkwVWljdXVDVGd0a1E4bmRKLVdkY3pfOTJvLVBjRnJIUDlYcmVsTmhsUDgxRW9BWEwzbC1jbnRLYWdqeU8teEVwU3ZFSXhIT05iLWgzeHc?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio to merge with San Diego biotech in deal backed by $505M in financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNNmhONGJnaDNUR0JKNzBfUVN4eDJXOHVzbUJ4UWNJVXFfWXZwX1F5UGtZTHB3ZWMyLUNNTWJRRGJiUnpTSWVIbFRVSWViNVdYdm9ObHBJVkxYOEVtUDF2bEFBSFg1X0VFYlJSYmZQTEdJeHhMZUplY2FRbHFKc0FwLXZ6MXJSWFVuQl9FU2lSVTQxbnRYYkdxbmZldXI4V3hpcHFLalotdkxQY3ZWSGF6aTJMUUQ?oc=5", "source_name": "Hartford Business Journal", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio Corp USD0.0001 share price | RLYB", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPOVIzc0FXeHhvZmxIYlB5cWRiZlRCU2tXZG9rMEJsQ2RaM0JnbUNhZTFkM0dFRlY2WE54ZDl1aERUSGYzMnNQazljQm4tVThPRFBTSnZVVjVTTUpkMlppcU9BSlhqV054cTNIcDQ1dm5QRVVjbjFXR3lJd0w3NEJNUA?oc=5", "source_name": "Hargreaves Lansdown", "published_at": "2026-02-10T05:21:49+00:00", "published_display": "10 Feb 2026 05:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio Announces Reverse Stock Split of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNaE9wWVREd2VyTGJvdnQ5b3B2TE5lMlJiZG5Mb0ZhZl83MGRRRGhwYml1WDM0UjFnaXVsMnh6OUY4SnE0OGU2V3lOQjdDRWgxX3pMWGI4Uy15VWU1X0x2dFlaSGhoTC02clRQNFZYdXR5dTVGUFRELWlvV09rdXRoZWNMeWpOSTRaSnoxVGxsejhQMTFjc3pRc3JVUUpFQmU4bzN6SXNMVy13aDBDUlZIMA?oc=5", "source_name": "Business Wire", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 Advances", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNSDJKMlpBLVBSdGVza1otWm1PZU52R09BTWgtR3QwWWFZV0I1emQxdWYxMXN2SnhaMEp3UC04eTZ6c1N0TXBXajJSbGprMHB0YTE2cGlxMDhVWnZGQjUyS1JVSV9vdVZjRjJqV1pWSXl6U0VVREE5VjNMZFJIVDJPLTk2U1JMTnFnT2s1dzdzai0xUQ?oc=5", "source_name": "Market source", "published_at": "2025-09-21T07:00:00+00:00", "published_display": "21 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rallybio (RLYB) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFBrN1BGMTVSMmRvWmhxTHVlamo5b09feTFuMkZhRklFRk1jcVF3QmJfOXZXeHJoYm00SDk5VlVFbGJVb3lIc0hhOU5LZWdVNTRqX3pKVmtSWU9zZw?oc=5", "source_name": "MarketBeat", "published_at": "2021-07-30T23:24:33+00:00", "published_display": "30 Jul 2021 23:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 89, "total_relevant": 51, "sentiment_summary": {"positive": 13, "negative": 6, "neutral": 32, "score": 53, "total": 51, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "deals", "primary_label": "Deals and strategy", "confidence": 74, "events": [{"event": "deals", "label": "Deals and strategy", "weight": 11.0, "count": 20}, {"event": "general", "label": "Market update", "weight": 9.35, "count": 17}, {"event": "earnings", "label": "Earnings", "weight": 5.5, "count": 12}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 13, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 15.73, "latest_week": "2026-07-10", "one_week_move": -0.5, "four_week_move": -1.2, "twelve_week_move": 91.4, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.355067, "market_dynamics_buy_signal": false, "relative_strength": 81.400135, "fair_value_gap": 29.5, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 59.2357, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.5% over one week, -1.2% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 50, "badges": [], "opportunities": [], "risks": [], "event_label": "Deals and strategy", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 9}, {"label": "Market source", "count": 7}, {"label": "TradingView", "count": 4}, {"label": "Investing.com", "count": 4}, {"label": "TradingKey", "count": 3}, {"label": "Business Wire", "count": 2}, {"label": "Quiver Quantitative", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 43}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Deals and strategy", "count": 20}, {"label": "Market update", "count": 17}, {"label": "Earnings", "count": 12}, {"label": "Regulatory and legal", "count": 1}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Deals and strategy", "tone": "neutral", "text": "74/100 classification confidence."}, {"label": "Company focus", "value": "43", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-0.5% over one week, -1.2% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Rallybio Corporation (NASDAQ: RLYB) to merge and rebrand as Avenzo Therapeutics"}], "updated_at": "2026-07-16T14:31:27.694168+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}